Axsome Therapeutics, Inc.
AXSM
$148.98
$1.170.79%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 26.19% | 19.98% | 6.11% | -20.05% | -54.07% |
| Total Depreciation and Amortization | 16.24% | 16.50% | 17.95% | 16.45% | 12.36% |
| Total Amortization of Deferred Charges | -22.46% | 0.98% | 3.03% | 2.56% | -3.24% |
| Total Other Non-Cash Items | -16.05% | 0.96% | -0.97% | 1.03% | 119.90% |
| Change in Net Operating Assets | -111.82% | -163.15% | 219.50% | 219.40% | 262.22% |
| Cash from Operations | 23.85% | 27.98% | 38.61% | 11.49% | 6.83% |
| Capital Expenditure | -77.73% | 10.80% | 16.26% | 53.61% | 67.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -77.73% | 10.80% | 16.26% | 53.61% | 67.33% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -39,885.00% | -55,357.88% | -653.37% | -- | -- |
| Issuance of Common Stock | 125.31% | 120.93% | -61.34% | -73.65% | -79.83% |
| Repurchase of Common Stock | -78.40% | -73.97% | -157.93% | -115.37% | -115.31% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.20% | -48.42% | 57.56% | 62.77% | 70.53% |
| Cash from Financing | 127.84% | 132.95% | -68.27% | -82.53% | -86.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 97.68% | 89.59% | -135.95% | -138.22% | -147.20% |